---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-076067"
form_type: "8-K"
ticker: "ABBV"
cik: "0001551152"
company_name: "AbbVie Inc."
filed_at: "2026-06-22T11:11:21+00:00"
generated_at: "2026-06-22T11:15:46.622928+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# AbbVie to acquire Apogee Therapeutics for $10.9B; adds zumilokibart pipeline

## Summary
- Total equity value ~$10.9 billion, AbbVie to pay $135.11 per share in cash for all outstanding shares.
- Apogee lead asset zumilokibart (APG777) is a half-life extended anti-IL-13 antibody for atopic dermatitis and asthma.
- Transaction expected to close in Q3 2026, subject to Apogee shareholder approval and regulatory clearances.
- Deal projected to be accretive to AbbVie adjusted diluted EPS beginning 2032; key shareholders support.
- AbbVie will host an investor conference call on June 22 at 8:00 a.m. CT to discuss the transaction.

## SEC filing metadata
- accession: 0001104659-26-076067
- form_type: 8-K
- ticker: ABBV
- cik: 0001551152
- company_name: AbbVie Inc.
- filed_at: 2026-06-22T11:11:21+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1551152/000110465926076067/0001104659-26-076067-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1551152/000110465926076067/tm2618365d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-076067
- JSON: https://secwatch.observer/filing/0001104659-26-076067.json
- Plain text: https://secwatch.observer/filing/0001104659-26-076067.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.